LOS ANGELES, CA / ACCESSWIRE / November 10, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Allergan plc ("Allergan" or the "Company") (NYSE: AGN) and/or Actavis plc concerning possible violations of federal securities laws between February 25, 2014 and November 3, 2016 inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Allergan made false and/or misleading statements and/or failed to disclose that: Allergan and Actavis engaged in conduct that would result in a Department of Justice ("DOJ") antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Allergan and Actavis lacked effective internal controls; and that as a result of the above, Allergan's and Actavis' public statements were materially false and misleading at all relevant times.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC